Send the following on WhatsApp
Continue to Chathttps://forschung.kssg.ch/en/projects/333-a-phase-iii-multicenter-randomized-double-blind-placebo-controlled-safety-study-of-xolair-omalizumab-in-patients-with-chronic-idiopathic-urticaria-ciu-who-remain-symptomatic-despite-treatment-with-h1-antihistamines-h2-blockers-andor-leukotriene-receptor-antagonists